Another Plaintiff Joins Chantix Side Effects MDL in Alabama
Plaintiff Gordon C. Loftis, through his Chantix lawyer, recently had his lawsuit joined to the ongoing Chantix multidistrict litigation (MDL) in the U.S. District Court, Northern District of Alabama (Southern).
Like the more than 2,400 other plaintiffs participating in the MDL, Loftis claims Chantix manufacturer Pfizer failed to warn him about serious side effects.
Chantix lawyer hired after suicide attempt
Loftis hired his Chantix attorney after suffering from severe depression and anxiety that eventually led to a suicidal ideation and a suicide attempt. Loftis attributes his suicidal implusles to use of Chantix.
Although researchers are trying to determine why Chantix causes suicidal thoughts in some patients, they’ve established that a link between Chantix use and suicide exists. During an 18-month period, the Food and Drug Administration (FDA) received nearly 300 reports related to Chantix depression.
On February 1, 2008, the FDA released a public health advisory about the risk of Chantix suicide. In 2009, the FDA required Pfizer to place a black box warning on the Chantix side effects label. The label addressed risks for “changes in behavior such as hostility, agitation, depressed mood, and suicidal thoughts or actions.”
According to the lawsuit complaint, this label change came about a year after Loftis started taking Chantix.
2012 means movement for Chantix multidistrict litigation
Plaintiffs represented in the Alabama MDL by a Chantix attorney claim Pfizer developed, marketed and sold a faulty product and then failed to warn users about the risks.
MDLs are created to address similar complaints brought against a common defendant in a timely manner.
Judge Inge P. Johnson is overseeing the MDL, and hopes to begin bellwether trials in October. Loftis vs. Pfizer was filed by the plaintiff’s Chantix lawyer in the U.S. District Court, Northern District of Alabama (Southern) April 23, 2012.